Literature DB >> 10347215

Interleukin-10 receptor signaling through the JAK-STAT pathway. Requirement for two distinct receptor-derived signals for anti-inflammatory action.

J K Riley1, K Takeda, S Akira, R D Schreiber.   

Abstract

Interleukin-10 (IL-10) is a cytokine that has pleiotropic effects on a variety of different cell types. Although many of the biologic responses induced by IL-10 are also induced by other cytokines, such as IL-6, IL-10 is relatively unique in its ability to potently inhibit production of pro-inflammatory cytokines in macrophages. In this study, we have used gain-of-function and loss-of-function genetic approaches to define the intracellular components involved in the different biologic actions of IL-10. Herein, we demonstrate that the ability of IL-10 to inhibit tumor necrosis factor alpha (TNFalpha) production in lipopolysaccharide-stimulated macrophages requires the presence of Stat3, Jak1, and two distinct regions of the IL-10 receptor intracellular domain. Macrophages deficient in Stat3 or Jak1 were unable to inhibit lipopolysaccharide-induced TNFalpha production following treatment with murine IL-10. Structure-function analysis of the intracellular domain of the IL-10 receptor alpha chain showed that whereas two redundant Stat3 recruitment sites (427YQKQ430 and 477YLKQ480) were required for all IL-10-dependent effects on either B cells or macrophages, expression of IL-10-dependent anti-inflammatory function required the presence on the intracellular domain of the IL-10 receptor of a carboxyl-terminal sequence containing at least one functionally critical serine. These results thus demonstrate that IL-10-induced inhibition of TNFalpha production requires two distinct regions of the IL-10 receptor intracellular domain and thereby establish a distinctive molecular basis for the developmental versus the anti-inflammatory actions of IL-10.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10347215     DOI: 10.1074/jbc.274.23.16513

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  111 in total

1.  IL-10 secretion and sensitivity in normal human intestine and inflammatory bowel disease.

Authors:  C Gasche; S Bakos; C Dejaco; W Tillinger; S Zakeri; W Reinisch
Journal:  J Clin Immunol       Date:  2000-09       Impact factor: 8.317

Review 2.  What does Stat3 do?

Authors:  David E Levy; Chien-kuo Lee
Journal:  J Clin Invest       Date:  2002-05       Impact factor: 14.808

Review 3.  Structure and function of interleukin-22 and other members of the interleukin-10 family.

Authors:  Daniela Barretto Barbosa Trivella; José Ribamar Ferreira-Júnior; Laure Dumoutier; Jean-Christophe Renauld; Igor Polikarpov
Journal:  Cell Mol Life Sci       Date:  2010-05-08       Impact factor: 9.261

4.  A network map of Interleukin-10 signaling pathway.

Authors:  Renu Verma; Lavanya Balakrishnan; Kusum Sharma; Aafaque Ahmad Khan; Jayshree Advani; Harsha Gowda; Srikanth Prasad Tripathy; Mrutyunjay Suar; Akhilesh Pandey; Sheetal Gandotra; T S Keshava Prasad; Subramanian Shankar
Journal:  J Cell Commun Signal       Date:  2015-08-08       Impact factor: 5.782

Review 5.  Virus-encoded homologs of cellular interleukin-10 and their control of host immune function.

Authors:  Barry Slobedman; Peter A Barry; Juliet V Spencer; Selmir Avdic; Allison Abendroth
Journal:  J Virol       Date:  2009-07-29       Impact factor: 5.103

6.  Toxicogenomic studies of the rat brain at an early time point following acute sarin exposure.

Authors:  Tirupapuliyur V Damodaran; Stephen T Greenfield; Anand G Patel; Holly K Dressman; Siomon K Lin; Mohamed B Abou-Donia
Journal:  Neurochem Res       Date:  2006-05-13       Impact factor: 3.996

Review 7.  Interferon-gamma and cancer immunoediting.

Authors:  Gavin P Dunn; Hiroaki Ikeda; Allen T Bruce; Catherine Koebel; Ravi Uppaluri; Jack Bui; Ruby Chan; Mark Diamond; J Michael White; Kathleen C F Sheehan; Robert D Schreiber
Journal:  Immunol Res       Date:  2005       Impact factor: 2.829

8.  Interleukin-10 targets p38 MAPK to modulate ARE-dependent TNF mRNA translation and limit intestinal pathology.

Authors:  D Kontoyiannis; A Kotlyarov; E Carballo; L Alexopoulou; P J Blackshear; M Gaestel; R Davis; R Flavell; G Kollias
Journal:  EMBO J       Date:  2001-07-16       Impact factor: 11.598

Review 9.  Leishmania interferes with host cell signaling to devise a survival strategy.

Authors:  Suvercha Bhardwaj; Neetu Srivastava; Raki Sudan; Bhaskar Saha
Journal:  J Biomed Biotechnol       Date:  2010-04-08

10.  STAT3-mediated up-regulation of BLIMP1 Is coordinated with BCL6 down-regulation to control human plasma cell differentiation.

Authors:  Sean A Diehl; Heike Schmidlin; Maho Nagasawa; Simon D van Haren; Mark J Kwakkenbos; Etsuko Yasuda; Tim Beaumont; Ferenc A Scheeren; Hergen Spits
Journal:  J Immunol       Date:  2008-04-01       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.